The IGBA urgently calls for global collaboration among stakeholders to protect the balance between innovation and access to medicines. A thriving off-patent sector is not a threat to innovation — it is essential to its continuation and sustainability.

The International Generic and Biosimilar medicines Association (IGBA), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.

The International Generic and Biosimilar medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its adoption of a new topic focused on the harmonisation of "Framework for Determining Utility of Comparative Efficacy Studies in Biosimilar Development Programs."